Australia to purchase 20 million more doses of Pfizer's COVID-19 vaccine - PM

Reuters

Published Apr 09, 2021 13:35

CANBERRA, April 9 (Reuters) - Australia will purchase another 20 million doses of Pfizer (NYSE:PFE)'s PFE.N COVID-19 vaccine, Prime Minister Scott Morrison said on Friday.

Australia on Thursday said it now recommended people under 50 are inoculated with the Pfizer vaccine in favour of that produced by AstraZeneca (NASDAQ:AZN) AZN.L citing rare blood clots.

Australia last year purchased 20 million doses of the Pfizer vaccine. However, as it needs additional supplies following the updated advice, Morrison said Canberra will double that order, with the latest batch to be delivered in the fourth quarter of 2021.

Get The App
Join the millions of people who stay on top of global financial markets with Investing.com.
Download Now

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes